About Akcea Therapeutics (NASDAQ:AKCA)
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$55.21 million
Price / Sales38.62
Price / CashN/A
Book Value$2.70 per share
Price / Book11.85
Return on EquityN/A
Return on AssetsN/A
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
Where is Akcea Therapeutics' stock going? Where will Akcea Therapeutics' stock price be in 2018?
4 Wall Street analysts have issued twelve-month price targets for Akcea Therapeutics' stock. Their predictions range from $20.00 to $30.00. On average, they expect Akcea Therapeutics' share price to reach $26.67 in the next twelve months. View Analyst Ratings for Akcea Therapeutics.
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Indivior (INVVY), FibroGen (FGEN), ABLYNX (ABLYF), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), Hikma Pharmaceutic (HKMPF), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), TESARO (TSRO), ACADIA Pharmaceuticals (ACAD), Halozyme Therapeutics (HALO), Clovis Oncology (CLVS), Evotec (EVTCY), Amicus Therapeutics (FOLD), China Biologic Products (CBPO), Ascendis Pharma A/S (ASND) and Puma Biotechnology (PBYI).
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Stanley T. Crooke M.D. Ph.D., Chairman of the Board (Age 72)
- Paula Soteropoulos, President, Chief Executive Officer, Director (Age 49)
- Michael Maclean, Chief Financial Officer (Age 52)
- Jeffrey M. Goldberg, Chief Operating Officer (Age 44)
- Elizabeth L. Hougen, Senior Vice President - Finance (Age 55)
- Louis St. L. O'Dea, Chief Medical Officer (Age 66)
- B. Lynne Parshall J.D., Director (Age 63)
- Edward M. Fitzgerald, Independent Director (Age 62)
- Christopher Gabrieli M.D., Independent Director (Age 57)
- Elaine Hochberg, Independent Director (Age 59)
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.
Has Akcea Therapeutics been receiving favorable news coverage?
News coverage about AKCA stock has trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Akcea Therapeutics earned a coverage optimism score of 0.22 on Accern's scale. They also assigned news stories about the company an impact score of 46.70 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Akcea Therapeutics' major shareholders?
Akcea Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.74%), Geode Capital Management LLC (0.31%), Altrinsic Global Advisors LLC (0.23%), Candriam Luxembourg S.C.A. (0.17%), Iguana Healthcare Management LLC (0.15%) and Schwab Charles Investment Management Inc. (0.10%). View Institutional Ownership Trends for Akcea Therapeutics.
Which institutional investors are selling Akcea Therapeutics stock?
Which institutional investors are buying Akcea Therapeutics stock?
AKCA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Iguana Healthcare Management LLC, Goldman Sachs Group Inc., Swiss National Bank, Altrinsic Global Advisors LLC, Wells Fargo & Company MN, Alliancebernstein L.P. and Virtus Fund Advisers LLC. View Insider Buying and Selling for Akcea Therapeutics.
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $32.00.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $2.15 billion and generates $55.21 million in revenue each year. Akcea Therapeutics employs 100 workers across the globe.
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (AKCA)MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akcea Therapeutics (NASDAQ:AKCA) Earnings History and Estimates Chart
Akcea Therapeutics (NASDAQ AKCA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2017||Q3 2017||($0.21)||($0.18)||$15.48 million||$13.45 million||View||N/A|
|8/8/2017||Q2 2017||($0.27)||$14.13 million||View||N/A|
Akcea Therapeutics (NASDAQ:AKCA) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.51 EPS
Next Year EPS Consensus Estimate: $1.19 EPS
Dividend History for Akcea Therapeutics (NASDAQ:AKCA)
No dividend announcements for this company have been tracked by MarketBeat.com
Akcea Therapeutics (NASDAQ AKCA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 29.14%
Akcea Therapeutics (NASDAQ AKCA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/19/2017||Ionis Pharmaceuticals Inc||Major Shareholder||Buy||3,125,000||$8.00||$25,000,000.00||28,884,540|| |
Akcea Therapeutics (NASDAQ AKCA) News Headlines
Akcea Therapeutics (NASDAQ:AKCA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akcea Therapeutics (NASDAQ:AKCA) Income Statement, Balance Sheet and Cash Flow Statement
Akcea Therapeutics (NASDAQ AKCA) Stock Chart for Friday, March, 23, 2018